Perrigo (PRGO) Competitors

$10.94 -0.19 (-1.66%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$11.10 +0.17 (+1.55%)

As of 06:13 AM Eastern

PRGO vs. CORT, NKTR, SUPN, OMER, and PCRX

Should you buy Perrigo stock or one of its competitors? MarketBeat compares Perrigo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Perrigo include Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Supernus Pharmaceuticals (SUPN), Omeros (OMER), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Corcept Therapeutics?

Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Corcept Therapeutics had 6 more articles in the media than Perrigo. MarketBeat recorded 8 mentions for Corcept Therapeutics and 2 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 0.72 beat Perrigo's score of 0.54 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Corcept Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 76.80%. Corcept Therapeutics has a consensus target price of $70.83, indicating a potential upside of 24.09%. Given Perrigo's higher probable upside, research analysts clearly believe Perrigo is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Corcept Therapeutics has a net margin of 6.14% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Corcept Therapeutics	6.14%	7.40%	5.76%

Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A
Corcept Therapeutics	$769.10M	7.97	$99.65M	$0.35	163.09

95.9% of Perrigo shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Perrigo has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Summary

Corcept Therapeutics beats Perrigo on 12 of the 17 factors compared between the two stocks.

How does Perrigo compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Nektar Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

In the previous week, Nektar Therapeutics had 25 more articles in the media than Perrigo. MarketBeat recorded 27 mentions for Nektar Therapeutics and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.54 beat Nektar Therapeutics' score of 0.43 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Nektar Therapeutics has higher earnings, but lower revenue than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	46.47	-$164.08M	-$8.42	N/A
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A

Nektar Therapeutics currently has a consensus target price of $149.63, suggesting a potential upside of 96.98%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 76.80%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Perrigo	-43.50%	9.96%	3.90%

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nektar Therapeutics beats Perrigo on 9 of the 16 factors compared between the two stocks.

How does Perrigo compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Supernus Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Supernus Pharmaceuticals and 2 mentions for Perrigo. Supernus Pharmaceuticals' average media sentiment score of 0.83 beat Perrigo's score of 0.54 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

95.9% of Perrigo shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Supernus Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$776.83M	3.84	-$38.55M	-$0.51	N/A
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Perrigo	-43.50%	9.96%	3.90%

Supernus Pharmaceuticals currently has a consensus target price of $62.17, suggesting a potential upside of 21.04%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 76.80%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Supernus Pharmaceuticals beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Omeros?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Omeros had 7 more articles in the media than Perrigo. MarketBeat recorded 9 mentions for Omeros and 2 mentions for Perrigo. Omeros' average media sentiment score of 0.85 beat Perrigo's score of 0.54 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Omeros has a beta of 2.66, meaning that its stock price is 166% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-72.14%	59.71%
Perrigo	-43.50%	9.96%	3.90%

Omeros currently has a consensus target price of $40.33, suggesting a potential upside of 180.48%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 76.80%. Given Omeros' stronger consensus rating and higher probable upside, equities analysts clearly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.8% of Omeros shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 12.9% of Omeros shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Omeros has higher earnings, but lower revenue than Perrigo. Omeros is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	-$0.50	N/A
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A

Summary

Omeros beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Pacira BioSciences?

Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

In the previous week, Pacira BioSciences had 9 more articles in the media than Perrigo. MarketBeat recorded 11 mentions for Pacira BioSciences and 2 mentions for Perrigo. Pacira BioSciences' average media sentiment score of 0.55 beat Perrigo's score of 0.54 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Pacira BioSciences	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Pacira BioSciences	0.70%	10.24%	5.47%

Perrigo presently has a consensus target price of $19.33, suggesting a potential upside of 76.80%. Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 27.60%. Given Perrigo's higher probable upside, research analysts clearly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A
Pacira BioSciences	$726.41M	1.25	$7.03M	$0.12	192.00

Summary

Pacira BioSciences beats Perrigo on 13 of the 16 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRGO vs. The Competition

Export

Metric	Perrigo	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.54B	$8.12B	$6.30B	$22.96B
Dividend Yield	10.43%	2.51%	2.79%	4.06%
P/E Ratio	-0.83	18.19	21.03	28.29
Price / Sales	0.36	7.64	548.94	24.50
Price / Cash	2.10	16.76	42.94	25.11
Price / Book	0.61	3.75	9.84	4.73
Net Income	-$1.43B	$223.05M	$3.55B	$1.07B
7 Day Performance	-6.82%	-2.05%	-0.52%	-1.11%
1 Month Performance	-4.66%	3.40%	1.21%	1.36%
1 Year Performance	-57.89%	1.89%	41.24%	24.41%

Perrigo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRGO Perrigo	4.2365 of 5 stars	$10.94 -1.7%	$19.33 +76.8%	-58.3%	$1.54B	$4.25B	N/A	8,100
CORT Corcept Therapeutics	3.986 of 5 stars	$51.60 +0.4%	$74.67 +44.7%	-19.1%	$5.52B	$761.41M	147.43	300	Analyst Upgrade Gap Up
NKTR Nektar Therapeutics	3.1551 of 5 stars	$86.89 +0.5%	$140.63 +61.8%	+613.2%	$2.92B	$55.23M	N/A	220	Trending News Earnings Report Analyst Forecast Analyst Revision
SUPN Supernus Pharmaceuticals	2.7832 of 5 stars	$48.63 +1.6%	$62.17 +27.8%	+59.1%	$2.76B	$718.95M	N/A	580	Gap Up High Trading Volume
OMER Omeros	3.1479 of 5 stars	$14.91 -1.0%	$40.33 +170.5%	+224.6%	$1.08B	N/A	N/A	210	News Coverage Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PRGO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perrigo (PRGO) Competitors

PRGO vs. CORT, NKTR, SUPN, OMER, and PCRX

How does Perrigo compare to Corcept Therapeutics?

Summary

How does Perrigo compare to Nektar Therapeutics?

Summary

How does Perrigo compare to Supernus Pharmaceuticals?

Summary

How does Perrigo compare to Omeros?

Summary

How does Perrigo compare to Pacira BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Perrigo (PRGO) Competitors

PRGO vs. CORT, NKTR, SUPN, OMER, and PCRX

How does Perrigo compare to Corcept Therapeutics?

Does the media prefer PRGO or CORT?

Do analysts prefer PRGO or CORT?

Is PRGO or CORT more profitable?

Which has preferable valuation and earnings, PRGO or CORT?

Do institutionals & insiders have more ownership in PRGO or CORT?

Which has more risk & volatility, PRGO or CORT?

Summary

How does Perrigo compare to Nektar Therapeutics?

Which has more risk & volatility, NKTR or PRGO?

Does the media favor NKTR or PRGO?

Which has stronger earnings and valuation, NKTR or PRGO?

Do analysts recommend NKTR or PRGO?

Is NKTR or PRGO more profitable?

Do institutionals and insiders have more ownership in NKTR or PRGO?

Summary

How does Perrigo compare to Supernus Pharmaceuticals?

Which has more risk & volatility, SUPN or PRGO?

Does the media favor SUPN or PRGO?

Do institutionals and insiders have more ownership in SUPN or PRGO?

Which has stronger earnings and valuation, SUPN or PRGO?

Is SUPN or PRGO more profitable?

Do analysts recommend SUPN or PRGO?

Summary

How does Perrigo compare to Omeros?

Does the media refer more to OMER or PRGO?

Which has more risk and volatility, OMER or PRGO?

Is OMER or PRGO more profitable?

Do analysts prefer OMER or PRGO?

Do insiders & institutionals have more ownership in OMER or PRGO?

Which has preferable earnings & valuation, OMER or PRGO?

Summary

How does Perrigo compare to Pacira BioSciences?

Does the media prefer PRGO or PCRX?

Which has more volatility and risk, PRGO or PCRX?

Is PRGO or PCRX more profitable?

Do analysts rate PRGO or PCRX?

Do institutionals & insiders hold more shares of PRGO or PCRX?

Which has higher valuation & earnings, PRGO or PCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO vs. The Competition

Perrigo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools